Publikationen in Zusammenarbeit mit Forschern von Universidad Autónoma de Madrid (99)

2023

  1. Control of a hippocampal recurrent excitatory circuit by cannabinoid receptor-interacting protein Gap43

    Nature Communications, Vol. 14, Núm. 1

  2. Importance of immunometabolic markers for the classification of patients with major depressive disorder using machine learning

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 121

2022

  1. Polyfunctionalized α-Phenyl-tert-butyl(benzyl)nitrones: Multifunctional Antioxidants for Stroke Treatment

    Antioxidants, Vol. 11, Núm. 9

  2. Relationship between immunometabolic status and cognitive performance among major depression disorder patients

    Psychoneuroendocrinology, Vol. 137

  3. Synthesis and Pharmacological Evaluation of New N-Sulfonylureas as NLRP3 Inflammasome Inhibitors: Identification of a Hit Compound to Treat Gout

    Journal of Medicinal Chemistry, Vol. 65, Núm. 8, pp. 6250-6260

2021

  1. (±)- BIGI-3h: Pentatarget-Directed Ligand combining Cholinesterase, Monoamine Oxidase, and Glycogen Synthase Kinase 3β Inhibition with Calcium Channel Antagonism and Antiaggregating Properties for Alzheimer's Disease

    ACS Chemical Neuroscience, Vol. 12, Núm. 8, pp. 1328-1342

2020

  1. In Vitro and in Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases

    ACS Chemical Neuroscience, Vol. 11, Núm. 22, pp. 3793-3801

  2. Na+ controls hypoxic signalling by the mitochondrial respiratory chain

    Nature, Vol. 586, Núm. 7828, pp. 287-291

2019

  1. Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer’s disease therapy

    Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 34, Núm. 1, pp. 479-489

  2. HIF1α Suppresses Tumor Cell Proliferation through Inhibition of Aspartate Biosynthesis

    Cell Reports, Vol. 26, Núm. 9, pp. 2257-2265.e4

  3. New Dual Small Molecules for Alzheimer's Disease Therapy Combining Histamine H3 Receptor (H3R) Antagonism and Calcium Channels Blockade with Additional Cholinesterase Inhibition

    Journal of Medicinal Chemistry, Vol. 62, Núm. 24, pp. 11416-11422

  4. Quinoxalinetacrine QT78, a cholinesterase inhibitor as a potential ligand for Alzheimer’s disease therapy

    Molecules, Vol. 24, Núm. 8

  5. Tacrines for Alzheimer's disease therapy. III. The PyridoTacrines

    European Journal of Medicinal Chemistry, Vol. 166, pp. 381-389

2018

  1. Pathway-specific control of striatal neuron vulnerability by corticostriatal cannabinoid CB 1 receptors

    Cerebral Cortex, Vol. 28, Núm. 1, pp. 307-322

  2. The APPswe/PS1A246E mutations in an astrocytic cell line leads to increased vulnerability to oxygen and glucose deprivation, Ca 2+ dysregulation, and mitochondrial abnormalities

    Journal of Neurochemistry, Vol. 145, Núm. 2, pp. 170-182

  3. AhR deletion promotes aberrant morphogenesis and synaptic activity of adult-generated granule neurons and impairs hippocampus-dependent memory

    eNeuro, Vol. 5, Núm. 4

  4. Corrigendum to “European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)” (Redox Biol. (2017) 13 (94–162)(S2213231717303373)(10.1016/j.redox.2017.05.007))

    Redox Biology

  5. Folic Acid Protects Against Glutamate-Induced Excitotoxicity in Hippocampal Slices Through a Mechanism that Implicates Inhibition of GSK-3β and iNOS

    Molecular Neurobiology, Vol. 55, Núm. 2, pp. 1580-1589

  6. R-Ras2 is required for germinal center formation to aid B cells during energetically demanding processes

    Science Signaling, Vol. 11, Núm. 532

2017

  1. European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)

    Redox Biology, Vol. 13, pp. 94-162